Precigen/$PGEN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Precigen

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Ticker

$PGEN
Sector
Primary listing

Employees

143

Precigen Metrics

BasicAdvanced
$930M
-
-$0.43
1.87
-

What the Analysts think about Precigen

Analyst ratings (Buy, Hold, Sell) for Precigen stock.

Bulls say / Bears say

On August 15, 2025, the U.S. FDA approved Precigen’s immunotherapy PAPZIMEOS for adults with recurrent respiratory papillomatosis, making it the first FDA-approved treatment for this rare disease and pushing shares up 81% premarket (Reuters).
As of March 31, 2025, Precigen held $81.0 million in cash, cash equivalents, and investments, enough to fund operations into 2026 and support its 2025 commercial launch plans (PRNewswire).
On September 3, 2025, Precigen secured a $125 million non-dilutive credit facility from Pharmakon Advisors, strengthening its financial position to support U.S. commercialization and global expansion of PAPZIMEOS (RTTNews).
Precigen’s first quarter 2025 net loss grew to $54.2 million (−$0.18 per share), mainly due to a $32.5 million non-cash increase in warrant liabilities, signaling continued profitability issues (PRNewswire).
On September 18, 2025, Director Randal J. Kirk sold 1,403,360 shares at an average price of $3.86, reducing his holding by more than 10%—potentially indicating insider doubts about Precigen’s near-term prospects (MarketBeat).
On May 15, 2025, HC Wainwright lowered its full-year 2025 EPS forecast for Precigen to ($0.37) from ($0.29), highlighting increased concerns about profitability as PAPZIMEOS approaches commercialization (Defense World).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

Precigen Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Precigen Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PGEN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs